CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.

Oncotarget · 2014 · PMC4279373 · PMID 25296973

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

In recurrent patients with high AR expression ( p = 0.023 ), there was a significant trend toward improved survival of those patients with high expression of CAMK2N1 (n = 19) compared to those with low CAMK2N1 expression (n = 20) in tumors (Figure. 1B ).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.